Sharon 2014.

Study name	Oral ketamine for suicidal ideation. Trial registration number: NCT02037503.
Methods	Allocation: double‐blind randomisation. Design: single‐centre (hospital). Setting: ambulatory patients living in the community. Follow‐up period: participants will be assessed each week during treatment for a total of three weeks, followed by a one week post‐treatment follow‐up period. Location: Tel Aviv, Israel.
Participants	Inclusion criteria: i) males and females; ii) between 18 and 65 years of age; iii) admitted to the emergency department following a suicide attempt severe enough to necessitate medical intervention. Exclusion criteria: not stated.
Interventions	Participants randomised to the intervention arm will receive oral administration of a sub‐anaesthetic dose of ketamine.
Outcomes	Primary outcome: scores on the Beck Scale for Suicidal ideation during treatment and for one week post‐treatment. Secondary outcomes: scores on Montgomery‐Åsberg Depression Rating Scale during treatment and for one week post‐treatment, treatment adherence measured as the proportion of patients who withdraw from the trial owing to the development of intolerable side‐effects, and the proportion of patients who engage in SH and/or make a suicide attempt during treatment and for one week post‐treatment.
Starting date	Start date: January, 2014. Proposed end date: January, 2016.
Contact information	Name: Dr. Haggai Sharon. Affiliation: Functional Brain Centre, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel. email:haggais@tlvmc.gov.il
Notes	Prof. Haggai Sharon very kindly provided unpublished information relating to this trial.